Wednesday, December 25, 2013

Global and China Separating Membrane Industry Research Report, 2013 - 2016: Market Overview

Global and China Separating Membrane Industry Report, 2013 - 2016

Separating membrance is a kind of thin-layer substance with selective penetration function. It is for the use of concentration, separation and purification, and is widely applied in the sectors such as environment, energy, chemical, electronics, pharmaceuticals and food.

To Read the Complete Report with TOC Visithttp://www.marketresearchreports.biz/analysis-details/global-and-china-separating-membrane-industry-report-2013-2016

In 2012, the global market scale of separating membrance products approached USD12 billion, of which, the market size of reverse osmosis membrance (including nanofiltration membrance), micro-filtration membrance and ultrafiltration membrance stood at around 95%. Worldwide, industrial players from Japan and the United States play a more dominant role, cases including Toray Industries, Mitsubishi Rayon, Asahi Kasei Corporationin all professional in micro-filtration and ultrafilatration membrance fields, as well as Hydranautics, The Dow Chemical Company, and GE in reverse osmosis membrance/nanofiltration membrance arenas.

China separating membrane market has witnessed robust development with the growth pace keeping at 20%-30% in last ten years, albeit as a later starter. In 2012, the size of China separating membrance products market approximated RMB12 billion, with the proportion worldwide soaring to 16.3%. it is projected that China separating membrance market will continue its growth rate by around 20% in the upcoming years and that the figure by 2016 will jump to roughly RMB25 billion.

An integrated membrance industrial system has taken shape in China, with major products covering reverse osmosis membrance, micro-filtration membrance and ultrafiltration membrance with the market scale making up around 92%. Other separating membrance products include electric-driven membrance, gas separation membrane, medical membrance, etc.

Reverse osmosis membrance features the widest application, with the domestic market being occupied by foreign companies. And Chinese industrial players represented by Vontron Technology and Hangzhou Water Treatment Technology Development Center hold only 15% market share.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/181689

China micro-filtration membrance and ultrafiltration membrance markets demonstrate the fiercest competition, with the market occupancy nationwide exceeding 60%. China has more than 100 micro-filtration membrance and ultrafiltration membrance manufacturers consisting of Beijing Origin Water Technology, MOTIMO, and LITREE. However, foreign counterparts, such as Toray Industries and Asahi Kasei Corporation, are still taking a dominant position in high-end fields such as ultrapure water for electronic industry use, electrophoresis paint recycling, pharmaceutical, and enzymic preparation fields.

Separating membrance is made from organic or inorganic materials. And inorganic materials are mainly ceramic and metal, while organic materials mainly refer to all kinds of chemical raw materials. For example, the reverse osmosis membrance is commonly made from aromatic polyamide, while micro-filtration membrance and ultrafiltration membrance is mainly made from PVDF, polysulfone, PES and PVC, etc. Presently, China has a small number of companies involving in the production of membrance raw materials. Coupled with unstable quality, China imports around 60% membrance raw material resin.

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/181689

The report highlights:

•    Market Scale, Product Structure and Competition Pattern in Global Separating Membrance Industry;
•    Market Scale, Product Structure ,Competition Pattern, Membrance Materials, Development Objectives in China Separating Membrance Industry;
•    Market Scale, Competition Pattern, and Development Trend of China Water Treatment Membrance Industry;
•    Overview and Competition Pattern of Other Separating Membrance Markets in China;
•    Operation, Separating Membrance Business, Development Prediction of 15 Separating Membrance Producers in China and Beyond.


Latest Reports:

Global and China Monoclonal Antibody Industry Report, 2013 - 2017: http://www.marketresearchreports.biz/analysis-details/global-and-china-monoclonal-antibody-industry-report-2013-2017                         

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal antibody market size will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017.

Driven by enhanced economic level, expanded scope of medical insurance reimbursement, as well as lower prices incurred by intensified competition, Chinese monoclonal antibody market is expected to continue to grow significantly. In 2013-2017, Chinese monoclonal antibody market will grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012).

The global monoclonal antibody industry is still dominated by European and American companies, especially, important monoclonal antibody products are mainly produced by Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson and other companies. In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Roche) stemmed from the above four companies. The global sales (including the sales of third parties) of these six monoclonal antibody agents totaled USD45 billion, accounting for 57.7% of the global.

Propelled by the optimistic market prospect, advancement of monoclonal antibody technologies and the upcoming patent expiration of several key monoclonal antibody agents, the research and industrialization of monoclonal antibody agents has become a global investment highlight, wherein the future market competition will be evident.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/181610

In September 2013, the Infliximab generic drug - Inflectra developed by South Korea Celltrion and the U.S. Hospira jointly was launched upon the approval of the EU EMA. In November 2013, the Trastuzumab generic drug developed by the U.S. Mylan and India Biocon together was available in the market under the permit of Drug Controller General Of India. Mylan will sell the product tagged with the brand name Hertraz in India in early 2014.

In addition, India Biocon's first anti-CD6 Alzumab (Itolizumab) for the treatment of chronic plaque psoriasis was approved to be sold in India in August 2013.

In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012.

 
China Medical Monitor Industry Report, 2013 - 2015: http://www.marketresearchreports.biz/analysis-details/china-medical-monitor-industry-report-2013-2015                                                         

In 2007-2011, the Chinese medical monitor market size rose from RMB1.16 billion to RMB3.08 billion at a CAGR of 27.8%. In 2012, the figure reached RMB3.86 billion, a year-on-year increase of 25.3%, of which, multi-parameter monitor market size accounted for more than 60%.

China is a major exporter of monitor, in 2006-2012 the export volume grew at a CAGR of 22.9%. From January to October of 2013 China’s export volume of medical monitors climbed 16.7% YoY. Meanwhile, many of high-end medical monitors in China are still dependent on imports, 80% of the medium- and high-end monitor market was occupied by General Electric (GE), Philips and other foreign brands.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/181227

Medical monitor pertains to the high-tech, high value-added product, with high levels of industry profit. In 2008-2013 China’s major monitor enterprises e.g. Mindray, Biolight and EDAN Instruments kept gross margin around 50%.

With the improvement of living standards and aging of population in China, medical monitor will be extended from medical institution to home health care, and household multi-parameter monitor will become a new growth engine of consumption, which will consolidate the market position of multi-parameter monitor. Meanwhile, accompanied by the family planning policy adjustments, obstetric monitor embraces a positive outlook.

The Chinese medical monitor market size is expected to achieve RMB7.42 billion in 2015, of which, multi-parameter monitor market size and obstetric care market size will be RMB4.412 billion and RMB588 million, respectively.

 
About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Blog: http://mrrfocuseconomics.blogspot.com/

No comments:

Post a Comment